Wire · opportunities
FDA clears Bayer's Hyrnuo in first-line lung cancer, amping up Hernexeos rivalry
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 9 September 2026 · Fusion42 review
The FDA granted Bayer's Hyrnuo accelerated approval as a first-line treatment for locally advanced or metastatic non-squamous NSCLC with HER2 mutations, expanding its use beyond prior therapies. This intensifies competition with Boehringer Ingelheim's Hernexeos, targeting the same rare patient subset.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 9 Sep 2026 and 10 Sep 2026.
◆ ◆ The Wire takeaway
You can now reposition your HER2-mutant lung cancer therapies to compete for first-line treatment despite initial second-line approvals. This clearing accelerates access to a tighter patient group, making market entry tougher but more valuable.
◆ Coverage
3 sources · first reported 9 Sep 2026 · latest 10 Sep 2026
◆ Related on Wire
◆ Topics